Expert: Addressing the High Cost of Middle Men in Supply Chain is Critical to Drug Spend Management
Cheryl Larson, president and CEO of Midwest Business Group on Health, discusses current efforts to manage drug spend and the high cost of specialty drugs on the market.
Pharmacy Times interviewed Cheryl Larson, president and CEO of the Midwest Business Group on Health (MBGH), to discuss the current efforts to manage drug spend and the high cost of specialty drugs on the market.
During the discussion, Larson addressed how the management of drug spend and the management of specialty drug prices are linked, how MGBH’s National Employer Initiative on Specialty Drugs is working to manage the higher costs of biologics and specialty drugs, and how issues relating to pharmacy benefit manager transparency on pricing affects drug spend. She also provided an overview of current trends in development that may have an impact on drug spend in the future.
